Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer (original) (raw)
Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial
Dorte Nielsen
European Journal of Cancer, 2014
View PDFchevron_right
Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer
Rosalía Caballero
Journal of Clinical Oncology, 2013
View PDFchevron_right
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer
Giuseppe Viale
The Breast, 2014
View PDFchevron_right
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Malcolm Reed
PLoS Medicine, 2010
View PDFchevron_right
Association of Menopausal Status, Expression of Progesterone Receptor and Ki67 to the Clinical Response to Neoadjuvant Chemotherapy in Luminal Breast Cancer
Susana Ramalho
Revista Brasileira de Ginecologia e Obstetrícia, 2019
View PDFchevron_right
Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information
Shelley Bull
Modern Pathology, 2014
View PDFchevron_right
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast
Gunter Von Minckwitz
Breast Cancer Research, 2008
View PDFchevron_right
Discordance Rate in Estrogen Receptor, Progesterone Receptor, HER2 Status, and Ki67 Index Between Primary Unifocal and Multiple Homogenous Breast Carcinomas and Synchronous Axillary Lymph Node Metastases Have an Impact on Therapeutic Decision
Orsolya Bauer
Applied Immunohistochemistry & Molecular Morphology, 2017
View PDFchevron_right
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
Olle Stål
Journal of Clinical Pathology, 2005
View PDFchevron_right
Prognostic value of estrogen and progesterone receptors in operable breast cancer: Results of a univariate and multivariate analysis
Yvon Graic, Bernard Asselain
Cancer, 1988
View PDFchevron_right
Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials
Stefan Michiels
Annals of Oncology, 2007
View PDFchevron_right
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
Gunter Von Minckwitz, Bernd Gerber
Breast Cancer Research, 2009
View PDFchevron_right
Progesterone Receptors, Pathological Complete Response and Early Outcome for Locally Advanced Breast Cancer – a Single Centre Study. (PPLB – 01)
Animesh Saha
Indian Journal of Surgical Oncology, 2016
View PDFchevron_right
Long-term Prognostic Impact of Immunohistochemical Estrogen Receptor Determinations Compared with Biochemical Receptor Determination in Primary Breast Cancer
Ulf-Håkan Stenman
Acta Oncologica, 1997
View PDFchevron_right
Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial
Alaa Ali
International Journal of Cancer, 2013
View PDFchevron_right
Comparison between her2, estrogen receptors and progesterone receptors in primary breast carcinomas and matched lymph node metastases
Ihab atta
Turkish Journal of Pathology, 2016
View PDFchevron_right
Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value
natalia valdivieso
Breast Cancer Research, 2011
View PDFchevron_right
Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study
Graham Colditz
Breast cancer research and treatment, 2011
View PDFchevron_right
Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy
Atilla Soran
Cancer, 2010
View PDFchevron_right
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
Giuseppe Viale
Breast Cancer Research, 2014
View PDFchevron_right
Can Estrogen Receptor, Progesterone Receptor, and Proliferative Index be Considered as Isolated Prognostic Factors of Overall Survival in Early luminal Breast Cancer?
G. Petrusevska
Open Access Macedonian Journal of Medical Sciences, 2021
View PDFchevron_right
Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen
Jorge Laura
Annals of Oncology, 2012
View PDFchevron_right
Immunohistochemical profile and clinical-pathological variables in breast cancer
Homero Gonçalves Júnior
Revista da Associação Médica Brasileira (English Edition), 2012
View PDFchevron_right
Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy
Howard Rockette
Breast Cancer Research and Treatment, 1983
View PDFchevron_right
TO STUDY THE CLINICAL AND PATHOLOGICAL STAGING OF BREAST CANCER AND TO CORRELATE THESE FINDINGS WITH STATUS OF THE TUMOR MARKERS
yogesh boddepalli
View PDFchevron_right
Short-term outcome of primary operated early breast cancer by hormone and HER-2 receptors
Wouter R L Hendrickx
Breast Cancer Research and Treatment, 2009
View PDFchevron_right
Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer
Filippo Montemurro
Annals of Oncology, 2006
View PDFchevron_right
Estrogen receptor quantitation and staging as complementary prognostic indicators in breast cancer: A study of 583 patients
William Godolphin
International Journal of Cancer, 1981
View PDFchevron_right
Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer
Ahmed Hasouna
Breast Cancer Research, 2012
View PDFchevron_right
Fractionated evaluation of immunohistochemical hormone receptor expression enhances prognostic prediction in breast cancer patients treated with tamoxifen as adjuvant therapy
Chiun-sheng Huang
Journal of Zhejiang University SCIENCE B, 2010
View PDFchevron_right
Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer
daniel yakubu
Breast Cancer Research and Treatment, 2012
View PDFchevron_right
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information
Zoran Kozomara
Clinical Medicine Insights: Oncology, 2014
View PDFchevron_right
Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: A single institutional experience
Aziza Nassar
International journal of clinical and experimental pathology
View PDFchevron_right